Vaginal Ring Holds Potential in Preventing HIV and Pregnancy by Angela Mohan on January 27, 2021 at 3:23 PM
Vaginal ring containing Dapivirine and levonorgestrel delivered sustained levels of drugs when used continuously for 90 days, levels likely sufficient to serve dual purpose for protecting against both HIV and unwanted pregnancy.
Results of the Phase I study of the 90-day dual-purpose ring are being presented at the HIV Research for Prevention (HIVR4P) Virtual Conference, or HIVR4P Virtual, which is taking place over the course of four days.
The study, MTN-044/IPM 053/CCN019, was conducted by researchers from the National Institutes of Health (NIH)-funded Microbicide Trials Network (MTN) in collaboration with NIH s Contraceptive Clinical Trials Network (CCTN) and is the first to evaluate the ring s use, as intended, for 90 days.
Low-dose aspirin may improve pregnancy chances for women with one or two prior miscarriages
Contrary to previous findings, low-dose aspirin therapy before conception and during early pregnancy may increase pregnancy chances and live births among women who have experienced one or two prior miscarriages, suggests a study by researchers at the National Institutes of Health. Rather than looking solely at the difference in pregnancy rates between women who were given aspirin and those receiving a placebo, the study also accounted for differences in total aspirin use between women who deviated from the daily regimen and those who adhered to it.
E-Mail
PITTSBURGH, 26 January 2021 - A vaginal ring containing the antiretroviral drug dapivirine and the contraceptive hormone levonorgestrel delivered sustained levels of each drug when used continuously for 90 days - levels likely sufficient to serve its dual purpose for protecting against both HIV and unwanted pregnancy, according to findings of a new study.
Results of the Phase I study of the 90-day dual-purpose ring are being presented at the HIV Research for Prevention (HIVR4P) Virtual Conference, or HIVR4P // Virtual, which is taking place over the course of four days: Jan. 27-28 and Feb. 3-4.
The study, MTN-044/IPM 053/CCN019, was conducted by researchers from the National Institutes of Health (NIH)-funded Microbicide Trials Network (MTN) in collaboration with NIH s Contraceptive Clinical Trials Network (CCTN) and is the first to evaluate the ring s use, as intended, for 90 days. In an earlier first-in-human study (MTN-030/IPM 041), also conducted by the MTN, women use
Results will inform development of long-acting antibody-based HIV prevention tools.
Scanning electromicrograph of an HIV-infected T cell. NIAID
An investigational anti-HIV antibody delivered intravenously once every eight weeks safely and effectively prevented acquisition of HIV strains sensitive to that antibody, but did not significantly reduce overall HIV acquisition after 80 weeks among participants in two multinational clinical trials. Known as the Antibody-Mediated Prevention (AMP) Studies, the Phase 2b trials are sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The studies are being conducted jointly by the HIV Vaccine Trials Network (HVTN) and HIV Prevention Trials Network (HPTN).
During the pandemic, relationships have mostly continued much as they were before, report researchers, though the happiest couples have seen a small boost.